Program
Elfetabart Drozuntecan
Also written as “BNT324” and “DB-1311”.
Its studies are mostly in Small Cell Lung Carcinoma · Prostatic Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioNTech | 22 open or running | phase 3since Jan 23, 2026 | Mar 19, 2025 | Sep 2028phase 2 · NCT06892548 |
| DualityBio | 11 open or running | phase 2since Jun 13, 2023 | Jun 13, 2023 | Dec 2027phase 2 · NCT05914116 |
Also a collaborator on its studies: BioNTech (Shanghai) Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 13, 2023First study: phase 2 study in Small Cell Lung CarcinomaNew to DualityBioDualityBio · NCT05914116 · 862 planned · United States, Australia, China and more
- Mar 19, 2025BioNTech’s first study: phase 2 study in Small Cell Lung CarcinomaNew to BioNTechBioNTech · NCT06892548 · 594 planned · United States, Australia, China and more
- Jan 23, 2026Phase 3 study in Metastatic Castration-resistant Prostate CancerPhase 3 reachedBioNTech · NCT07365995 · 736 planned · United States, Australia, Belgium and more
Ahead
- Dec 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaDualityBio · NCT05914116
- Sep 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaBioNTech · NCT06892548
- Feb 2031Primary completion: phase 3 study in Metastatic Castration-resistant Prostate CancerBioNTech · NCT07365995
TargetBeta
“An antibody-drug conjugate (ADC) composed of elfetabart, a humanized monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276), that is ”NCIt, by rule
Other programs on CD276
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risvutatug rezetecan | Hansoh Pharmaceutical Group | phase 3 | 30 |
| ifinatamab deruxtecan | Merck | phase 3 | 16 |
| tambotatug pelitecan | MediLink Therapeutics (Suzhou) | phase 3 | 13 |
| Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 | CSPC Pharmaceutical Group | phase 3 | 5 |
| Anti-B7-H3 Antibody-drug Conjugate MHB088Crule | Minghui Pharmaceutical | phase 3 | 4 |
| Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101rule | tj-biopharma-co-ltd | phase 3 | 3 |
| Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01rule | radiopharm-theranostics-ltd | phase 2 | 1 |
| Autologous Anti-B7-H3 CAR T-cells BCB-276rule | brainchild-bio-inc | phase 2 | 1 |
| Anti-B7-H3/CD28 Bispecific Antibody XmAb808rule | Xencor | phase 1 | 2 |
| Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034rule | ideaya-biosciences | phase 1 | 1 |
| Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001rule | neok-bio-inc | phase 1 | 1 |
| HLX316 | Fosun Pharma | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07365995Metastatic Castration-resistant Prostate Cancer · United States, Australia, Belgium and more | 3 | Recruiting | BioNTech | Feb 2031 | 736 |
| NCT06892548Small Cell Lung Carcinoma · United States, Australia, China and more | 2 | Recruiting | BioNTech | Sep 2028 | 594 |
| NCT05914116Small Cell Lung Carcinoma · United States, Australia, China and more | 2 | Recruiting | DualityBio | Dec 2027 | 862 |
How it is read
Names in the registry
- “BNT324”, 2 entries
- “DB-1311”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 2 studies
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.